Hot Deals:
a v thomas 15,555.00 (3.70 %) adtech 29.10 (0.34 %) agarwal bolts 1,200.00 (-0.83 %) amol minechem 520.00 (-16.13 %) anand i-power 20.00 anglo french 350.00 (-5.41 %) apl metals 42.01 (0.02 %) arkfin investments 50.00 arohan 115.00 (-2.54 %) assam carbon 195.00 (-4.88 %) atlas copco 10,000.00 (1.01 %) auckland international 129.00 (-0.77 %) axles 190.00 (2.70 %) balmer lawrie 199.00 (1.02 %) bharat hotels 144.00 (-0.69 %) bima mandi 700.00 bira 650.00 (3.83 %) boat 715.00 (-1.38 %) c & s electric 545.00 (7.92 %) cable corporation 15.00 capgemini 10,700.00 (1.86 %) care health 154.00 (1.99 %) carrier aircon 276.00 (0.36 %) cial 163.00 (1.24 %) csfbl 365.00 (-3.44 %) csk 160.00 (-1.84 %) dalmia refract 130.00 (4.00 %) dfm foods 467.00 dsp merrill lynch 1,000.00 east india pharma 49.00 (2.08 %) eaton fluid 440.00 (-2.22 %) electronica plastic 4,100.00 (-0.24 %) elgi ultra 400.00 elofic 2,050.00 (4.06 %) esl steel 32.00 (-3.03 %) fincare business 43.00 fincare sfbl 191.00 (0.53 %) finopaytech 115.00 (-3.36 %) flipkart india 231,001.00 (0.00 %) frick india 3,800.00 (2.70 %) gkn drive 1,090.00 (-0.91 %) go digit general insurance ltd 354.00 (1.14 %) godavari bio 71.00 (1.43 %) hdb financial 640.00 (-0.78 %) hdfc ergo 370.00 (1.70 %) hdfc securities 10,500.00 (1.94 %) hella india 575.00 (4.55 %) hero fincorp 1,050.00 (1.94 %) hexaware 530.00 (1.92 %) hicks 1,700.00 (-0.58 %) hira ferro 130.00 (8.33 %) honeywell electrical 3,333.00 (-1.97 %) icex 0.10 (-0.10 %) ikf finance 214.00 (4.90 %) incred financial 100.00 india carbon 945.00 (-0.53 %) india exposition 144.00 (-1.37 %) indian potash 1,390.00 (-0.71 %) indofil 650.00 (-2.99 %) infinite computer 405.00 (1.25 %) inkel 12.00 (-1.64 %) ixigo 87.00 (-1.14 %) jana sfbl 75.00 kel 550.00 (3.77 %) kial 104.00 (-0.95 %) klm axiva 17.50 (-1.13 %) kurlon limited 310.00 (1.31 %) lava 96.00 (-1.03 %) manipal housing 72.50 (0.69 %) manjushree tech 930.00 (3.33 %) martin & harris 1,070.00 (-0.93 %) merino 2,530.00 (-0.78 %) minosha 282.00 (0.71 %) mkcl 345.00 (1.47 %) mobikwik 360.00 (2.86 %) mohan meakin 1,450.00 (3.57 %) mohfl 10.90 (-8.40 %) msei 0.91 (-1.09 %) msil 55.00 (1.85 %) nayara energy 200.00 (2.56 %) nayara energy ncd 255.00 (-1.92 %) ncdex 275.00 ncl buildtek 229.00 (0.88 %) ncl holdings 65.00 (3.17 %) nse 3,250.00 (1.56 %) orbis financial 90.00 (9.76 %) oswal minerals 63.00 (-3.08 %) otis 3,500.00 (-2.78 %) oyo 64.00 (-1.54 %) panasonic appliances 295.00 (0.68 %) panasonic avc 29.10 (0.34 %) paymate india 505.00 (-4.72 %) pharmeasy 20.80 (-0.95 %) philips 950.00 (-3.06 %) philips domestic 580.00 (1.75 %) pnb metlife 70.00 proyuga adtech 25.00 purity flexpack 20.00 ramaraju surgical 320.00 (3.23 %) rasoi 31,500.00 (0.32 %) reliance gic 330.00 (-2.94 %) resins plastics 423.00 (0.71 %) ring plus 404.00 (-0.25 %) rrl 2,500.00 (-1.96 %) sab miller 305.00 (0.66 %) sbi amc 890.00 (-1.11 %) scottish assam 446.00 (0.68 %) shriram life 261.00 (0.38 %) sigachi lab 39.00 (-2.74 %) signify 1,400.00 (7.69 %) simpson & company 1,000,000.00 smile micro 52.00 (-1.89 %) sportskeeda 3,303.00 sterlite power 480.00 (1.05 %) studds 770.00 (-2.53 %) svsml 430.00 (-2.27 %) swiggy 361.00 (0.28 %) t stanes 750.00 (2.74 %) tata capital 178.00 (1.71 %) tata tech 875.00 (-0.57 %) teesta agro 85.00 (4.94 %) trl krosaki 1,255.00 (0.40 %) utkarsh core 135.00 (-1.46 %) vikram solar 350.00 (2.94 %) waree energie 600.00
×

Arch Pharma Share Price

Company Name
Arch Pharma Labs Limited
Last Traded Price (LTP)
90.00
% Change
+ 3.45 %
Scrip Name
Arch Pharma
ISIN No.
INE182F01017
PAN No.
AACCM0306Q
Face Value
10
No. of Outstanding Shares
151,923,000
Market Capitalization
1,367.31 Crore
Book value
15.087
P/BV
5.9654
EPS
123.052
PE ratio
0.731
Available on
nsdlcdsl
ROFR Require
No

Arch Pharma Labs Limited Delisted Share - Company Overview

ARCH PHARMA LABS LIMITED is a pharmaceutical company aligned across two business verticals viz. Products and Services. The Products business of the company comprises the manufacture and sale of Active Pharmaceutical Ingredients (“API”) and Intermediates to innovator and generic pharmaceutical players in both domestic and international markets including the regulated markets. In services business of the company includes Contract Research and Manufacturing Services (“CRAMS”). Currently, the company owns and manages 9 multipurpose manufacturing facilities.

The Company has a diversified portfolio and offers more than 120 products ( over 65 APIs and over 55 Intermediates) across various therapeutic segments, such as lipid-lowering agents, oncology, anti-platelet agents, anti-asthmatic,anti-retroviral, anti-anginal, calcium channel blockers, anti-hypertensive,anti-histamine, anti-diabetic, anti-protozoal, anti-fungal, anti-emetic, proton pump inhibitors, expectorant, anti-depressant, decongestant, anti-convulsant, psychostimulant, hypnotic, anti-parkinsonian, anti-gout, analgesic, and others.

The Company provides contract manufacturing, custom synthesis, and contract research services comprising route selection, process development, optimization, analytical development, stability studies, safety studies, scale-up to technology transfer, clinical-trial manufacturing, and commercial manufacture.

Arch Pharmalabs Limited has technology tie-ups with Codexis (USA), Orochem Technologies (USA), and DSM (Netherlands). The use of these technologies helps the company to implement various green chemistry initiatives which are not only environmentally friendly but also reduce production costs.

Incorporation Details of Arch Pharma Labs Limited

CIN of Arch Pharma Labs

U24231MH1993PLC150891

Registration Date of Arch Pharma Labs

02 April 1993

Category/Sub-category of Arch Pharma Labs

Company Limited by Shares

Arch Pharma Labs Registered office address and contact details

3rd Floor, Titanic Building, Chandivali Farm Road,

Nr. HDFC Bank, Andheri (East), Mumbai - 400072.

Tel. : +91-22-4287 1210

Arch Pharma Labs Registrar and Transfer Agent address and contact details

Link Intime India Private Limited

C-101, 247 Park, L.B.S Marg,

Vikhroli (West), Mumbai - 400083,

Tel: 022-25946970

Principal Business Activities of Arch Pharma Labs Limited

Name and Description of main products/services

NIC Code of the product/service

% to total turnover of the Company

Pharmaceutical products

21002 & 21005

100%

Board of Directors of Arch Pharma Labs Limited

Mr. Ajit Kamath (Chairman & Managing Director)

Mr. Rajendra Kaimal (Executive Director & CFO)

Mr. Ashish Ujagare (Executive Director)

Dr. Sunil Pitroda (Independent Director)

Particulars of Subsidiaries and Associates Companies of Arch Pharma Labs 

Name of the Company

Subsidiary/Associate

% of shares held

Arch Life SciencesLimited

Subsidiary

58.46%

Arch FinechemicalsLimited

Subsidiary

88.95%

Arch Pharmalabs FZLLC

Subsidiary

100.00%

Kobo Biotech Limited

Associate

44.95%

Shareholding Pattern of Arch Pharma Labs Limited (As of 31-03-2020)

S. No.

Shareholders’ Name

Number of shares

% of total Shares of the company

1

Arch Impex Private Limited

5,54,05,664

36.47%

2

Arch PharmachemLimited

2,11,81,000

13.94%

3

ArchAgroIndustriesPrivate Limited

61,54,754

4.05%

4

AMR InvestmentsPrivate Limited

19,76,681

1.30%

5

Arch Herbals Private limited

62,42,076

4.11%

6

Public Shareholding

6,09,62,901

40.12%

 

Total

15,19,23,076

100.00%

Industry Outlook

The Global pharmaceutical industry is valued at around US$ 1250 billion. The US market alone accounts for 48% of the market. India and China each stand at US$ 53 billion and US$ 190 billion respectively. India is the largest provider of generic drugs and is fulfilling around 20% of the global demand.

In the Active Pharmaceutical Ingredients (API) Industry, if we see the units approved by USFDA, US leads with 28% approval rating, Europe with 26%, and India & China with 18% and 13% respectively. It is the best time for India to focus on building and improving its API manufacturing and export capabilities. According to Statistics, the Indian API market is projected to grow at a CAGR of 8.57% from 2020 to 2026. The Government of India has announced Rs. 6,940 Crore Production Linked Incentive (PLI) scheme to boost drug manufacturing in India. The scheme is mainly aimed at reducing imports through the promotion of domestic manufacturing of Active Pharmaceutical Ingredients (APIs) and Drug Intermediates.

Pharmaceutical Companies are continuously increasing outsourcing research activities to academic and private contract research organizations (CROs) to become and stay competitive in the market. After the COVID 19 pandemic, the pharmaceutical industry has gotten a new direction and is currently experiencing dynamic changes. That is why to reduce their R&D expenses, the companies to a significant extent are now relying on outsourcing service providers. Based on this, the opportunities available to India are Custom Chemical Synthesis or CCS, clinical trials, and contract manufacturing or CRAMS. However, the most scalable opportunity for Indian companies lies in contract manufacturing or CRAMS. This is because CRAMS supplies are linked to the success of a product post commercialization and can provide relatively stable revenues.

 

Annual Report

Arch Pharma Labs Annual Report 2018-19

Download

Arch Pharma Labs Annual Report 2019-20

Download

Arch Pharma Labs Annual Report 2020-21

Download
Wealth Wisdom - WWIPL
Support Megha Support Neha